Drug Profile
AP 1030
Alternative Names: AP1030Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Action Pharma
- Class Antihyperglycaemics; Guanidines; Small molecules
- Mechanism of Action Melanocortin type 1 receptor modulators; Melanocortin type 4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in France (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Denmark (PO)
- 10 Mar 2010 Safety and pharmacodynamics data from a phase Ib proof-of-concept trial in obese volunteers released by Action Pharma